Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Genetic Screens02:46

Genetic Screens

5.5K
Genetic screens are tools used to identify genes and mutations responsible for phenotypes of interest. Genetic screens help identify individuals or a group of people at risk of developing  genetic diseases and help them with early intervention, targeted therapy, and reproductive options.
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which...
5.5K
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

15.1K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
15.1K
Cancer Prevention02:59

Cancer Prevention

7.5K
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
7.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Differences in overall survival for invasive epithelial ovarian cancer by race and ethnicity: results from the Ovarian Cancer Association Consortium.

British journal of cancer·2026
Same author

Saturation Genome Editing reveals the functional impact of RAD51D <i>and</i> XRCC2 variants.

bioRxiv : the preprint server for biology·2026
Same author

Various dimensions of sexual self-concept in middle-aged men after vasectomy: a matched analysis.

BJU international·2026
Same author

Genomic analysis of BCG unresponsive non-muscle-invasive bladder cancer identifies drivers of sensitivity to intravesical Gemcitabine/Docetaxel.

bioRxiv : the preprint server for biology·2026
Same author

Perioperative Apalutamide in High-Risk Localized Prostate Cancer.

The New England journal of medicine·2026
Same author

Polygenic risk score with KLK3 SNP-SNP interaction pairs for predicting prostate cancer aggressiveness.

Communications medicine·2026
Same journal

Genetically proxied inhibition of cholesterol-lowering drug targets and survival in HPV-positive and non-HPV driven head and neck cancer: a multicentre MR study.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·2026
Same journal

Retraction: Menstrual Factors, Reproductive History and Liver Cancer Risk: Findings from a Prospective Cohort Study in Chinese Women.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·2026
Same journal

Optimizing the Uptake and Completion of the Cervical Cancer Screening Continuum: Opportunity Knocks, Including at Home.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·2026
Same journal

Sex Differences in Cancer Stage at Diagnosis of Nonreproductive Solid Organ Tumors in the United States, 2015 to 2022.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·2026
Same journal

Evaluation of the 4Kscore in EPIC: Reply.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·2026
Same journal

Evaluation of the 4Kscore in EPIC: Letter.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·2026
See all related articles

Related Experiment Video

Updated: Dec 17, 2025

Detection and Isolation of Cancer in Prostate Biopsies Using Stimulated Raman Histology and Artificial Intelligence
08:05

Detection and Isolation of Cancer in Prostate Biopsies Using Stimulated Raman Histology and Artificial Intelligence

Published on: June 10, 2025

1.0K

A Genetic Risk Score to Personalize Prostate Cancer Screening, Applied to Population Data.

Minh-Phuong Huynh-Le1,2, Chun Chieh Fan2, Roshan Karunamuni1,2

  • 1Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, California.

Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology
|June 26, 2020
PubMed
Summary
This summary is machine-generated.

A polygenic hazard score (PHS) can personalize prostate cancer screening by estimating individual risk-equivalent ages. This genetic risk assessment helps determine optimal screening initiation for better prostate cancer detection.

More Related Videos

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

17.0K
Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes
08:32

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes

Published on: May 23, 2025

925

Related Experiment Videos

Last Updated: Dec 17, 2025

Detection and Isolation of Cancer in Prostate Biopsies Using Stimulated Raman Histology and Artificial Intelligence
08:05

Detection and Isolation of Cancer in Prostate Biopsies Using Stimulated Raman Histology and Artificial Intelligence

Published on: June 10, 2025

1.0K
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

17.0K
Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes
08:32

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes

Published on: May 23, 2025

925

Area of Science:

  • Genetics and Genomics
  • Oncology
  • Preventive Medicine

Background:

  • A polygenic hazard score (PHS), based on 54 single nucleotide polymorphism (SNP) genotypes, has been validated for its association with clinically significant prostate cancer.
  • PHS has also demonstrated improved accuracy in prostate cancer screening.

Purpose of the Study:

  • To assess the potential impact of PHS-informed screening strategies for prostate cancer.
  • To evaluate how individualized genetic risk information can influence prostate cancer screening decisions.

Main Methods:

  • Combined UK population incidence data and data from the Cluster Randomized Trial of PSA Testing for Prostate Cancer to estimate age-specific prostate cancer incidence.
  • Calculated age-specific incidence rates for different PHS risk percentiles using hazard ratios (HRs) from the ProtecT prostate cancer trial.
  • Derived risk-equivalent age and calculated the positive predictive value (PPV) of PSA testing using PHS-adjusted age groups.

Main Results:

  • A 19-year difference in the expected age at diagnosis for clinically significant prostate cancer was observed between the 1st and 99th PHS percentiles.
  • Men in the 1st PHS percentile reach the 50-year-standard risk level at age 60, while those in the 99th percentile reach it at age 41.
  • The positive predictive value (PPV) of PSA testing was higher in men with higher PHS-adjusted ages.

Conclusions:

  • PHS offers individualized estimates of risk-equivalent age for clinically significant prostate cancer.
  • Screening initiation for prostate cancer can potentially be adjusted based on an individual's PHS.
  • Personalized genetic risk assessments hold promise for informing prostate cancer screening decisions.